TABLE 3.
Characteristic | Female Participants |
Male Participants |
||||
---|---|---|---|---|---|---|
N a | OR (95% CI) or β Coefficient (SE) |
P | N a | OR (95% CI) or β Coefficient (SE) |
P | |
All youth | ||||||
Any sexual activity with casual partnerb | 7447 | 2.96 (1.85–4.74) | <.001 | 6655 | 0.97 (0.50–1.88) | .920 |
Ever had sex for money | ||||||
Wave I | 7346 | 11.74 (4.51–30.57) | <.001 | 6564 | c | |
Wave III | 7480 | 1.48 (0.65–3.33) | .340 | 6699 | 1.55 (0.41–5.84) | .520 |
Ever had vaginal intercourse | ||||||
Wave I | 7449 | 3.01 (1.82–4.99) | <.001 | 6667 | 0.86 (0.43–1.72) | .660 |
Wave III | 7442 | 2.97 (1.20–7.34) | .020 | 6664 | 5.12 (1.13–2.22) | .040c |
Youth who reported a history of vaginal intercourse onlyd |
||||||
Condom use at most recent intercourse | ||||||
Wave I | 2767 | 0.60 (0.33–1.11) | .110 | 2640 | 1.87 (0.85–4.09) | .120 |
Wave III | 5950 | 0.68 (0.43–1.09) | .110 | 5106 | 0.85 (0.50–1.44) | .540 |
Age at first sexual activitye | 6528 | −1.48 (0.22) | <.001 | 5680 | 0.01 (0.39) | .990 |
No. of partners, vaginal sex evere | 6465 | 2.22 (0.79) | .006 | 5620 | 1.35 (1.64) | .410 |
No. of partners, vaginal sex in previous yeare | 6498 | −0.08 (0.09) | .390 | 5642 | −0.16 (0.33) | .640 |
No. of times had vaginal sex in previous yeare |
5159 | 29.80 (16.35) | .070 | 4683 | −7.66 (16.59) | .650 |
Frequency of condom use in previous yeare | 5945 | 0.87 (0.54–1.39) | .560 | 5099 | 0.62 (0.34–1.13) | .120 |
Sex with partner with STI in previous yeare | 6319 | 1.20 (0.55–2.61) | .640 | 5501 | 1.13 (0.32–4.06) | .850 |
Sex with intravenous drug user in previous yeare |
6587 | 2.31 (0.81–6.55) | .120 | 5734 | 0.38 (0.06–2.39) | .300 |
OR indicates odds ratio.
N = total number included in analysis (ie, with complete data) for this outcome.
Analysis conducted at Wave II.
No participants who reported a history of sex for money at this wave were in the foster care group.
Analyses were restricted to participants who reported a history of ever having vaginal sex in the wave of data being evaluated for outcomes in this section.
Analyses conducted at Wave III.